
Thirteen participants met the study’s response criterion, while three remain in the pivotal phase ahead of final results expected in December.
Rezolute said preliminary results from its Phase 3 upLIFT study in tumor hyperinsulinism showed that the primary efficacy endpoint had been achieved. The November 5 evaluation found 13 participants met the response criterion.
The endpoint measures whether patients achieve at least a 50% reduction in glucose infusion rate. Of the 13 responders, 12 also stopped intravenous glucose completely. Three participants remain in the pivotal phase, including two who have not yet met the response criterion.
Rezolute expects to report topline results and statistical analysis by mid-December 2026. Ersodetug remains investigational, and the company’s announcement did not report final study results.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.